GlassScriptPhysician profile
Feroz A Padder
NPI 1942291737
$1,953.80
in general payments reported to CMS, 2019-2025
13 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.49 · 2020: $1,338 · 2021: $27.80 · 2022: $164 · 2023: $116 · 2024: $61.30 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,315.76 | 2019-2020 | |
| Medtronic, INC. | $123.91 | 2022-2023 | Linq II |
| Pfizer INC. | $114.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $78.96 | 2020-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $65.74 | 2024-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.41 | 2024-2025 | Lifevest |
| Amgen INC. | $47.24 | 2022 | |
| Edwards Lifesciences Corporation | $35.25 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $29.46 | 2023-2025 | |
| Abbott Laboratories | $24.16 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Tactile Systems Technology INC | $19.66 | 2023 | Flexitouch Plus, Entre Plus |
| Axsome Therapeutics, INC. | $19.44 | 2025 | Symbravo |
| Amarin Pharma, INC. | $19.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feroz Padder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.